Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
£102.04 -186.00 (-1.79%)
As of 12:38 PM Eastern

AZN vs. GSK, ITH, SOPH, HCM, INDV, GRI, SLS, ERGO, SLN, and AMYT

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include GSK (GSK), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Indivior (INDV), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs. Its Competitors

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, AstraZeneca had 4 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 4 mentions for GSK. AstraZeneca's average media sentiment score of 0.48 beat GSK's score of -0.08 indicating that AstraZeneca is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
GSK
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.3%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca13.01% 17.76% 7.68%
GSK 8.02%18.08%9.56%

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£66.95B2.93£8.71B£364.8327.97
GSK£31.14B1.83£2.50B£61.9122.63

AstraZeneca presently has a consensus price target of GBX 8,380, indicating a potential downside of 17.88%. GSK has a consensus price target of GBX 1,783.33, indicating a potential upside of 27.28%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
GSK
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

51.0% of AstraZeneca shares are held by institutional investors. Comparatively, 45.3% of GSK shares are held by institutional investors. 0.0% of AstraZeneca shares are held by insiders. Comparatively, 1.6% of GSK shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AstraZeneca has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Summary

AstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£196.33B£93.26B£5.49B£2.96B
Dividend Yield1.23%2.50%5.39%5.02%
P/E Ratio27.9723.0627.43146.56
Price / Sales2.93158.79398.66240,164.98
Price / Cash38.8917.5936.1327.97
Price / Book3.882.998.025.25
Net Income£8.71B£3.43B£3.16B£5.90B
7 Day Performance0.59%0.26%2.21%1.11%
1 Month Performance-4.08%-0.59%4.50%5.65%
1 Year Performance-15.11%-0.39%36.02%82.18%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
1.9785 of 5 stars
£102.04
-1.8%
GBX 8,380
-17.9%
-14.0%£196.33B£66.95B27.9783,500
GSK
GSK
3.7662 of 5 stars
GBX 1,390
-1.1%
GBX 1,783.33
+28.3%
-6.3%£56.40B£31.14B22.4570,212
ITH
Ithaca Energy
N/AGBX 157.60
-0.4%
N/A+25.8%£3.29B£3.55B18.00220
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
HCM
HUTCHMED
N/AGBX 227
+3.7%
N/A-19.0%£2.46B£771.01M-57.941,760
INDV
Indivior
3.09 of 5 stars
GBX 1,084
+9.9%
GBX 1,650
+52.2%
-7.5%£1.69B£1.40B-898.791,000Gap Up
GRI
Grainger
3.2584 of 5 stars
GBX 220.02
-1.7%
GBX 317.50
+44.3%
-10.0%£1.62B£276.05M-1,466.79372News Coverage
Dividend Increase
SLS
Standard Life UK Smaller Companies Trust
N/AN/AN/AN/A£715.41M£222.48M3.3710
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down

Related Companies and Tools


This page (LON:AZN) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners